How Representative Are the Patients Included in the CV Outcome Trials With SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational Study

Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/dom.13612
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Effects of SGLT2 Inhibitors in the Treatment of a Population With Type 2 Diabetes Mellitus

Endocrine Abstracts
2016English

Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Cardiorenal Disease Is the Costliest CVD in Type 2 Diabetes: A Large Long-Term Observational Study

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2020English

SGLT2 Inhibitors: The Future for Treatment of Type 2 Diabetes Mellitus and Other Chronic Diseases

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis

Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2017English

A Prospective Study of Depression and Mortality in Patients With Type 2 Diabetes: The Fremantle Diabetes Study

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2005English

Encounters by Patients With Type 2 Diabetes--Complex and Demanding: An Observational Study

Annals of Family Medicine
Family Practice
2006English

Protocol of a Prospective Observational Study on the Relationship Between Glucose Fluctuation and Cardiovascular Events in Patients With Type 2 Diabetes

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy